Clinical Trial Results - Cancer Currents Blog
Reports on findings from cancer clinical trials, with commentary from leading researchers on how the trial results will affect patient care.
-
For Children with Neuroblastoma, Trial Results Highlight Continued Evolution of TreatmentFor many children with high-risk neuroblastoma, receiving two separate stem cell transplants is more beneficial than receiving one, according to the results of an NCI-supported clinical trial conducted by the Children’s Oncology Group.
-
Pediatricians’ Offices Can Help Parents Quit Smoking, Study ShowsResearchers tested a program that trains pediatricians’ offices to provide smoking cessation treatment to parents during visits with their child’s doctor. The approach is intended to reach adults who are motivated to quit to protect their child’s health.
-
Study Tests Immunotherapy in People with Cancer and Autoimmune DiseasesAn NCI-funded clinical trial is testing the immunotherapy drug nivolumab (Opdivo) in people who have advanced cancer and an autoimmune disease, such as rheumatoid arthritis, lupus, or multiple sclerosis, who are often excluded from such trials.
-
Targeted Drug Erdafitinib Benefits Some Patients with Advanced Bladder CancerNew clinical trial findings confirm that the targeted therapy erdafitinib (Balversa) can benefit patients with advanced bladder cancer whose tumors have a genetic alteration in one of the four FGFR genes.
-
Can Some Women Treated for Endometrial Cancer Forgo Radiation after Surgery?Some women with endometrial cancer may be able to receive less intensive treatment, chemotherapy and no radiation, without increasing their risk of the disease recurring within 5 years, according to the results of a randomized clinical trial.
-
Trial Highlights Complexities of Targeted Therapy for Pancreatic CancerOlaparib (Lynparza) may be beneficial for some people with advanced pancreatic cancer who have inherited mutations in the BRCA1 or BRCA2 genes, according to results from the POLO trial.
-
More Treatment Options Emerging for Some Men with Metastatic Prostate CancerIn two large clinical trials, the drugs enzalutamide (Xtandi) and apalutamide (Erleada), respectively, combined with the androgen deprivation therapy, improved the survival of men with metastatic prostate cancer that still responds to hormone-suppressing therapies.
-
Drug Shows Promise in Slowing Progression of Smoldering Myeloma to CancerThe drug lenalidomide (Revlimid) may delay the progression of smoldering myeloma to multiple myeloma, according to preliminary results from a clinical trial.
-
When Cancer Spreads to Bone, A Single Dose of Radiation Therapy May Control PainNew findings from a clinical trial suggest that a single dose of radiation therapy may control painful bone metastases as effectively as multiple lower doses of radiation therapy.
-
Tagraxofusp Proves Effective for BPDCN, A Rare Blood CancerNew findings from a clinical trial of the drug tagraxofusp confirm its efficacy against the rare blood cancer blastic plasmacytoid dendritic cell neoplasm (BPDCN).
-
A Vaccine to Treat Non-Hodgkin Lymphoma Advancing in Clinical TrialsIn some people with non-Hodgkin lymphoma (NHL), treating a single tumor with an in situ vaccine can help to shrink, or eliminate, tumors in other parts of the body, findings from a small clinical trial suggest.
-
Immunotherapy Drug with Two Targets Shows Promise against HPV-Related CancersThe investigational immunotherapy drug bintrafusp alfa (also called M7824), a bifunctional fusion protein, shrank the tumors of some patients with advanced HPV-related cancers, according to results from a phase 1 clinical trial.
-
Trial Examines Value of Lymph Node Surgery in Advanced Ovarian CancerSurgery to remove all the lymph nodes in the area around an advanced ovarian tumor did not improve survival in a recent randomized clinical trial. The study also found systematic lymphadenectomy was associated with more frequent serious complications.
-
Targeted Therapy–Immunotherapy Combinations Effective for Advanced Kidney CancerIn two clinical trials, combination treatments that included an immune checkpoint inhibitor and axitinib (Inlyta) led to better outcomes for patients with advanced kidney cancer than treatment with sunitinib (Sutent), the standard initial therapy.
-
Darolutamide Delays the Spread of Some Prostate CancersThe investigational drug darolutamide can help delay the spread of prostate cancer in some men with the disease, a recent clinical trial shows. In addition, the drug caused fewer side effects than similar prostate cancer drugs.
-
UK Clinical Trial Compares E-cigarettes, Nicotine-Replacement Products for Smoking CessationResearchers in the United Kingdom have found that e-cigarettes combined with counseling may be more helpful to smokers trying to quit tobacco than counseling and nicotine-replacement products, such as patches, gums, and lozenges.
-
Treatment for Children with Leukemia Also Effective for Adolescents, Young AdultsA clinical trial found that an intensive treatment regimen developed specifically for children with acute lymphoblastic leukemia is also effective for older adolescents and young adults with the disease.
-
Immunotherapy Effective in Alveolar Soft Part SarcomaPeople with advanced alveolar soft part sarcoma (ASPS), a rare cancer, appear to benefit from a type of immunotherapy called an immune checkpoint inhibitor, according to results from a small clinical trial.
-
Whole- and Partial-Breast Radiation Effective at Preventing Breast Cancer from ReturningIn women with early-stage breast cancer, two clinical trials have shown that both whole- and partial-breast radiation therapy are effective at preventing the cancer from returning after breast-conserving surgery.
-
Vitamin D Supplements Don’t Reduce Cancer Incidence, Trial ShowsIn the largest-ever randomized trial testing vitamin D for cancer prevention, the supplement did not lower the risk of developing cancer. The Vitamin D and Omega-3 Trial (VITAL) includes a nationally representative sample of nearly 26,000 participants.